Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) priced an underwritten offering of 3,581,000 Class A shares plus warrants, and up to 1,463,000 pre-funded warrants, alongside a concurrent registered direct sale of 71,607 shares to officers and directors.

Gross proceeds are expected to be about $9.8 million, with up to an additional $21.7 million possible if all pre-funded, Series A and Series B warrants are exercised in cash.

AI-generated analysis. Not financial advice.

Positive

• Approximately $9.8 million in expected gross proceeds before expenses
• Up to $21.7 million additional cash if all warrants are exercised
• Offering priced at $1.955, matching the last sale price on May 18, 2026
• Participation by existing investor Bain Capital Life Sciences and Armistice Capital
• Insider participation via 71,607 shares in a concurrent registered direct offering

Negative

• Issuance of up to roughly 5.1 million new shares plus warrant coverage dilutes existing holders
• Warrants with terms up to 5 years may create ongoing stock overhang

News Market Reaction – RPID

-0.77%

2 alerts

-0.77% News Effect

+8.9% Peak Tracked

-$694K Valuation Impact

$89.47M Market Cap

0.5x Rel. Volume

On the day this news was published, RPID declined 0.77%, reflecting a mild negative market reaction. Argus tracked a peak move of +8.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $694K from the company's valuation, bringing the market cap to $89.47M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Underwritten offering gross proceeds: $9.8 million Potential additional proceeds: $21.7 million Maximum offering size: $32 million +5 more

8 metrics

Underwritten offering gross proceeds $9.8 million Expected gross proceeds from offering and concurrent registered direct offering

Potential additional proceeds $21.7 million If all pre-funded, Series A and Series B warrants are exercised for cash

Maximum offering size $32 million Total potential proceeds including warrant exercises mentioned in headline

Shares in underwritten offering 3,581,000 shares Class A common stock offered with accompanying Series A and B warrants

Pre-funded warrant shares 1,463,000 shares Pre-funded warrants in lieu of common, with additional Series A and B warrants

Series A warrant exercise price $1.955 per share Warrants exercisable six months after issuance, expiring one year later

Series B warrant exercise price $2.34 per share Warrants exercisable six months after issuance, expiring in five years

Concurrent insider purchase 71,607 shares Directors and officers buying in separate registered direct offering

Market Reality Check

Price: $1.9800 Vol: Volume 224,133 is 1.42x t...

normal vol

$1.9800 Last Close

Volume Volume 224,133 is 1.42x the 20-day average of 157,656, indicating elevated trading ahead of the offering. normal

Technical At $1.955, shares trade below the $3.23 200-day MA and sit close to the $1.91 52-week low.

Peers on Argus

RPID fell 5.56% while at least 2 sector peers (e.g., ARAY -5.67%, HYPR -2.76%) a...

2 Down

RPID fell 5.56% while at least 2 sector peers (e.g., ARAY -5.67%, HYPR -2.76%) also moved down (median about -4.2%), suggesting broader medical-device weakness alongside stock-specific offering pressure.

Historical Context

5 past events · Latest: May 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 13	Q1 2026 earnings	Positive	-6.5%	Reported Q1 revenue growth but wider net loss and reaffirmed guidance.
May 06	Earnings date set	Neutral	+1.2%	Announced timing and webcast details for Q1 2026 results release.
Mar 12	FY25 earnings	Positive	-21.8%	Reported record Q4 and 2025 revenue with 2026 growth guidance.
Mar 12	Commercial order	Positive	-21.8%	Announced follow-on multi-system Growth Direct order from Samsung Biologics.
Mar 10	Conference participation	Neutral	+6.0%	Disclosed participation in KeyBanc healthcare forum with virtual Q&A.

Pattern Detected

Recent history shows multiple sharp selloffs on fundamentally positive or mixed updates, indicating a tendency for the stock to decline on news, especially around earnings and commercial milestones.

Recent Company History

Over the last few months, Rapid Micro Biosystems has emphasized revenue growth and commercialization progress but against persistent losses. Record Q4 and full-year 2025 results on Mar 12 and reiterated 2026 guidance still coincided with a -21.8% move. Q1 2026 earnings on May 13 showed revenue of $8.0M but a wider net loss, with shares down 6.45%. Commercial wins like the Samsung Biologics follow-on order also saw negative reactions. Against this backdrop, today’s equity-and-warrant financing adds capital but further highlights dilution risk.

Market Pulse Summary

This announcement details an equity financing structured with common stock, pre-funded warrants and ...

Analysis

This announcement details an equity financing structured with common stock, pre-funded warrants and two warrant series, targeting initial gross proceeds of about $9.8M and potential additional cash of $21.7M. It follows a period of revenue growth but ongoing net losses and cash burn highlighted in recent filings. Investors may focus on how the new capital affects runway, the degree of dilution from shares and warrants, and future operational milestones such as system placements and margin progress.

Key Terms

underwritten offering, pre-funded warrants, registered direct offering, Series A warrants, +4 more

8 terms

underwritten offering financial

"today announced the pricing of its underwritten offering consisting of 3,581,000 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

pre-funded warrants financial

"in lieu of common stock, to certain investors, pre-funded warrants, with an exercise price of $0.01 per share"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registered direct offering financial

"in a separate registered direct offering. All of the shares, pre-funded warrants"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

Series A warrants financial

"accompanying Series A warrants to purchase an aggregate of 3,581,000 shares"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B warrants financial

"and Series B warrants to purchase an aggregate of 3,581,000 shares of Class A common stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

shelf registration statement on Form S-3 regulatory

"pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276081)"

A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.

prospectus supplement regulatory

"The final prospectus supplement and accompanying prospectus relating to and describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Securities and Exchange Commission regulatory

"previously filed with the U.S. Securities and Exchange Commission (“SEC”) on December 15, 2023"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. Not financial advice.

Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering

LEXINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (“Rapid Micro Biosystems”) (Nasdaq: RPID), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the pricing of its underwritten offering consisting of 3,581,000 shares of its Class A common stock and accompanying Series A warrants to purchase an aggregate of 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase an aggregate of 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu thereof), and (ii) in lieu of common stock, to certain investors, pre-funded warrants, with an exercise price of $0.01 per share, to purchase an aggregate of up to 1,463,000 shares of its Class A common stock and accompanying Series A warrants to purchase an aggregate of 1,463,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase an aggregate of 1,463,000 shares of Class A common stock (or pre-funded warrants in lieu thereof). The Class A common stock and pre-funded warrants are being sold in combination with accompanying Series A and Series B warrants, each representing the right to purchase one share of Class A common stock (or a pre-funded warrant in lieu thereof). The accompanying warrants consist of (i) Series A warrants with an exercise price of $1.955 per share that is exercisable six months from the date of issuance and will expire one year from the date of issuance and (ii) Series B warrants with an exercise price of $2.34 per share that is exercisable six months from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of Class A common stock and accompanying Series A and Series B warrants is $1.955, representing the Company's last sale price on May 18, 2026. The combined offering price of each pre-funded warrant and accompanying Series A and Series B warrants is $1.945. Bain Capital Life Sciences, an existing investor, and Armistice Capital LLC, a healthcare-focused institutional investor, are participating in the offering.

In addition to the shares sold in the underwritten offering described above, Rapid Micro Biosystems has entered into a securities purchase agreement with certain of its officers and directors providing for the concurrent sale of 71,607 shares of Class A common stock and accompanying Series A warrants to purchase an aggregate of 71,607 shares of Class A common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.955 per share and Series B warrants to purchase an aggregate of 71,607 shares of Class A common stock (or pre-funded warrants in lieu thereof) with an exercise price of $2.34 per share, at a combined price of $1.955, in a separate registered direct offering.

All of the shares, pre-funded warrants and accompanying Series A and Series B warrants in the offering and concurrent registered direct offering being sold by Rapid Micro Biosystems. The gross proceeds to Rapid Micro Biosystems from the offering and concurrent registered direct offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $9.8 million. If all of pre-funded warrants, Series A warrants and Series B warrants sold in this offering are exercised for Class A common stock in cash, we expect to receive an additional $21.7 million. The offering is expected to close on May 20, 2026, subject to the satisfaction of customary closing conditions.

TD Cowen and Lake Street Capital Markets, LLC are acting as joint book-running managers for the offering.

The shares of Class A common stock, pre-funded warrants and accompanying Series A and Series B warrants and shares of Class A common stock (or pre-funded warrants in lieu thereof) issuable upon the exercise of the Series A and Series B warrants are being offered by Rapid Micro Biosystems in the offering pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276081), that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on December 15, 2023 and declared effective on December 26, 2023. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov.

Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: TD Securities (USA) LLC by mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, TDManualrequest@broadridge.com; or by accessing the SEC’s website at www.sec.gov.

The concurrent registered direct offering is anticipated to close on a date agreed to between the parties, subject to the satisfaction of customary closing conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Rapid Micro Biosystems’ beliefs and expectations regarding the offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the offering, and Rapid Micro Biosystems’ research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the offering and concurrent registered direct offering on the anticipated terms, or at all, market conditions and statements regarding the expected gross proceeds of the offering and concurrent registered direct offering, timing of closing of the offering and concurrent registered direct offering, the satisfaction of customary closing conditions related to the offering and sale of securities and Rapid Micro Biosystems’ ability to complete the offering and registered direct offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Rapid Micro Biosystems’ most recent annual report on Form 10-K filed on March 12, 2026 and subsequent quarterly reports on Form 10-Q, filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Rapid Micro Biosystems’ other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. Any forward-looking statements contained in this press release represent Rapid Micro Biosystems’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Rapid Micro Biosystems explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Contact:

Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com

Media Contact: media@rapidmicrobio.com

FAQ

What did Rapid Micro Biosystems (RPID) announce about its May 2026 stock offering?

Rapid Micro Biosystems announced pricing of an underwritten equity offering plus a concurrent registered direct offering, targeting about $9.8 million in gross proceeds. According to the company, the deal includes common shares, pre-funded warrants, and Series A and Series B warrants.

How much capital will Rapid Micro Biosystems (RPID) raise from the May 2026 offering?

Rapid Micro Biosystems expects approximately $9.8 million in gross proceeds before fees from the offerings. According to the company, it could receive an additional $21.7 million in cash if all pre-funded, Series A and Series B warrants are fully exercised.

What are the pricing terms of the RPID stock and warrant offering on May 18, 2026?

Each RPID common share plus Series A and B warrants is priced at $1.955, matching the May 18, 2026 last sale price. According to the company, each pre-funded warrant plus accompanying warrants is priced at $1.945 per unit.

What are the exercise prices and expirations of RPID Series A and Series B warrants?

RPID Series A warrants have a $1.955 exercise price, are exercisable six months after issuance, and expire one year later. According to the company, Series B warrants have a $2.34 exercise price and expire five years after becoming exercisable.

Who is participating in Rapid Micro Biosystems (RPID) May 2026 equity financing?

Bain Capital Life Sciences and Armistice Capital are investing about $9.8 million, with further upside from warrant exercises. According to the company, certain directors and officers are also buying 71,607 shares in a concurrent registered direct offering.

When is the closing date for Rapid Micro Biosystems (RPID) May 2026 offering?

The underwritten offering is expected to close on May 20, 2026, subject to customary conditions. According to Rapid Micro Biosystems, the concurrent registered direct offering will close on a mutually agreed date, also subject to standard closing conditions.